Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
| Autor: | Aroda, V.R., Ahmann, A., Cariou, B., Chow, F., Davies, M.J., Jódar, E., Mehta, R., Woo, V., Lingvay, I. |
|---|---|
| Zdroj: | In Diabetes & Metabolism October 2019 45(5):409-418 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect